|

Ibrutinib Clinical Trials

27 actively recruiting trials across 16 locations

Also known as: BTK Inhibitor PCI-32765, CRA 032765, CRA-032765, CRA032765, Imbruvica, JNJ-54179060, IMBRUVICA, PCI 32765, PCI-32765, PCI32765

Other7 trials

A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)
Phase 1/2
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Phase 3
Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia
CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma
Phase 2
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Phase 2
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
Phase 1/2
Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)
Phase 2

Tucson, Arizona3 trials

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

The University of Arizona Cancer Center - North Campus /ID# 242219

Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Banner University Medical Center - Tucson

Phase 2
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Banner University Medical Center - Tucson

Phase 2

Bethesda, Maryland2 trials

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

National Institutes of Health Clinical Center

Phase 1/2
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

National Institutes of Health Clinical Center

Phase 1

Boston, Massachusetts2 trials

Mosunetuzumab for CLL MRD Clearance

Brigham & Women's Hospital

Phase 1/2
Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Dana Farber Cancer Institute

Phase 1/2

Mobile, Alabama1 trial

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

USA Mitchell Cancer Institute ( Site 0014)

Phase 3

Phoenix, Arizona1 trial

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

St. Joseph's Hospital and Medical Center

Phase 1/2

Anaheim, California1 trial

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Pacific Cancer Medical Center, Inc

Phase 3

Cerritos, California1 trial

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

The Oncology Institute Clinical Research

Phase 2

Duarte, California1 trial

A Long-term Extension Study of PCI-32765 (Ibrutinib)

City of Hope Cancer Center

Phase 3

Fresno, California1 trial

Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

University of California, San Francisco (UCSF) Fresno

Phase 2

Sacramento, California1 trial

Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia

University of California Davis Comprehensive Cancer Center

Phase 2

Jacksonville, Florida1 trial

Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Mayo Clinic in Florida

Phase 2

Augusta, Georgia1 trial

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

Augusta University, Georgia Cancer Center

Phase 1

Minneapolis, Minnesota1 trial

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

University of Minnesota/Masonic Cancer Center

Phase 1/2

Basking Ridge, New Jersey1 trial

A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 1

Portland, Oregon1 trial

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

OHSU Knight Cancer Institute

Phase 1/2

Houston, Texas1 trial

Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

M D Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.